$1445 | Single User
$4995 | Site License
$10115 | Global License

Meeting KOL Needs: What Pharma Needs to Know
[Published by FirstWord Pharma]

Published by FirstWord Pharma: 01 Feb 2012 | 5 | In Stock
Related Topics: Cancer



The role of the Key Opinion Leader (KOL) has changed over the past 30 years. And it's about to change again.

Once viewed with suspicion by their non-consulting peers, clinicians are now considered less significant if they do not collaborate with the pharmaceutical industry. Yet with the implementation this year of the Physician Payment Sunshine Act (PPSA), that role is about to come under scrutiny once again.

How will transparency legislation affect KOL-industry collaborations? While some KOLs feel it could herald the end of such relationships, a wide-ranging FirstWord poll has found they have other, equally pressing issues. From how pharma utilises their expertise in planning drug trials to how it engages them professionally, KOLs are raising concerns about the state and future of their work with industry.


Report Overview

In Meeting KOL Needs: What Pharma Needs to Know, FirstWord taps into the mindsets of 33 leading international KOLs to discover how they view their industry work and where they want—and need—their collaborations to go. From KOL views on feedback, trial work and how follow-ups could be improved to invaluable insight on the PPSA's potential impact and how pharma cutbacks have negatively affected their knowledge base, the report exposes KOLs' major concerns. Based on in-depth, qualitative interviews and analysis, the report offers the industry an open window into the KOL relationship and how it can be strategically improved.


Key Report Features

  • Insight on how the forthcoming PPSA will affect KOL-industry ties

  • Discussion by KOLs on how pharma can best utilise their expertise in trial design and drug development

  • Analysis of core issues facing KOL-industry relations and how to move forward

  • Unparalleled access to KOL views on collaboration, diminishing pharma industry contacts, post-trial feedback, the use of digital media and the development of new technologies and therapies

  • Puchase Reasons

    Key Benefits

  • Insight into the thinking of 33 leading KOLs from across the United States, Canada and Europe

  • Strategic thinking and analysis on how KOL-industry collaborations can be improved

  • Examples of how to identify shortfalls in KOL management and where to go next

  • Key Questions Asked

  • In which areas is the industry not fully utilising KOLs and what new avenues can be created to do so?

  • What are the reasons for KOLs' widespread disagreement with the PPSA?

  • How have staff cutbacks in the pharmaceutical industry affected KOL collaboration?

  • To what extent do KOLs want more involvement in drug-development work?

  • How can the industry improve engagement, collaboration and feedback with KOLs?

  • Who Would Benefit From This Report?

  • Medical and scientific affairs directors

  • Clinical trial executives

  • Key account and territory managers

  • Marketing, brand and sales managers

  • Medical Science Liaisons

  • Business development executives

  • Regulatory and government affairs professionals

  • Key quotes

    “The PPSA has made the relationship become much more restrictive and defensive. Because of this fear of being tarnished on both sides, from the company's side and the KOL side, there's less interaction, there's less collaboration.” – Dr Christoph Correll, Albert Einstein College of Medicine, New York.

    “It’s frustrating, new people are just not as receptive. It’s too difficult to find the right people to talk to. Before we knew the medical director directly and personally, but now we've got to go through this quagmire of people to get to the right person.” – Professor David Vesole, John Theurer Cancer Center at HUMC, NJ.

    “I think that pharma is so big that although it works with KOLs, it doesn’t do very much listening to KOLs.” – Professor Laurence Steinman, Stanford University School of Medicine, California.

    Expert Views

  • Professor Laurence Steinman, professor of neurology and neurological sciences, pediatrics and genetics, Stanford University School of Medicine, US.

  • Dr Maurie Markman, senior vice president of clinical affairs and national director for medical oncology, Cancer Treatment Centres of America, US.

  • Professor Mark Freedman MD, professor of Neurology, Ottawa Hospital Research Institute, Canada

  • Professor Aaron Miller, medical director, Corinne Goldsmith Dickinson Centre for Multiple Sclerosis, Mount Sinai School of Medicine, New York, US.

  • Professor David Vesole, M., PhD, co- chief of the myeloma division and director of myeloma research at the John Theurer Cancer Center at HUMC, Hackensack, NJ, US.

  • Professor Douglas Jeffery, MD, PhD, associate professor of neurology, the Department of Neurology, The Multiple Sclerosis and Movement Disorders Centre at Advance Neurology at Cornerstone Health Care Winston-Salem, North Carolina, US.

  • Professor Lisa Licitra, MD, Head and Neck Medical Oncology Unit, Cancer Medicine Department, Istituto Nazionale Tumori, Italy

  • Professor Riccardo Audisio, MD, consultant surgical oncologist, St Helens Teaching Hospital, St Helens, UK.

  • Professor Werner Hacke, professor and chairman of the Department of Neurology, University of Heidelberg, Germany

  • Professor Raymond Hupperts, professor of neurology, Academic MS Centre Limburg, Orbis Medical Centre, the Netherlands
  • Table of Contents
    for Meeting KOL Needs: What Pharma Needs to Know [Published by FirstWord Pharma]

    • 1.Introduction


      3.Executive summary

      4.KOLs' view of the current pharma relationship

      4.1. How KOLs view their role

      4.2. KOLs' engagement with pharma

      4.3. Continuing Medical Education support from pharma

      5.Internal challenges to the KOL-pharma relationship

      5.1. Diminishing interaction with pharma personnel

      5.2. Staff changeover is a problem

      5.3. Lack of knowledge is a frustration for KOLs

      5.4. Pharma has its own agenda

      6.External challenges to the KOL-pharma relationship

      6.1. New regulation affecting the KOL-pharma relationship

      6.2. Misconceived regulations make collaboration less appealing

      7.What would KOLs most like to experience from pharma in future?

      8.What would KOLs not like to experience from pharma in the future?

      9.Key factors for an ideal relationship with pharma

      10.Ways to improve the KOL-industry relationship

      11.KOL biographies

    Additional Details


    FirstWord Pharma

    Publisher Information


    5 |

    Number of Pages


    Report Format


    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Global and Chinese Meeting Software Industry, 2017 Market Research Report
    The 'Global and Chinese Meeting Software Industry, 2012-2022 Market Research Report' is a profession...
    20 Dec 2017 by Prof Research USD $3,000 More Info
    MSL stakeholder engagement: meeting expectations
    MSL Stakeholder Engagement–Meeting ExpectationsIn this report, FirstWord identifies practical soluti...
    01 Jul 2017 by FirstWord Pharma USD $695 More Info
    MSL stakeholder engagement- meeting expectations
    MSL Stakeholder Engagement–Meeting ExpectationsIn this report, FirstWord identifies practical soluti...
    01 Jul 2017 by FirstWord Pharma USD $695 More Info
    Real World Data -- Meeting payer needs
    How to adjust your Real World Data provision to address the real needs of payersDrug costs are spira...
    01 May 2017 by FirstWord Pharma USD $2,245 More Info
    Pharma and the Changing US Payer Environment: Meeting the demands of Accountable Care Organizations (ACOs)
    IntroductionThere’s a revolution happening...and it’s going to change the way pharma thinks. As the ...
    01 Nov 2013 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Meeting KOL Needs: What Pharma Needs to Know [Published by FirstWord Pharma] | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types


    Buy now using our secure payment system.

    We Stock...